SEC Form 4 · accession 0001209191-18-056332

Sarepta Therapeutics, Inc. · SRPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Sandesh Mahatme

Officer — EVP, CFO & CBO

Period of report

Oct 24, 2018

Accepted (ET)

Oct 26, 2018 · 6:43 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000873303

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 24, 2018	M	9,596	$23.85	A	48,381	D
Common Stock	Oct 24, 2018	M	39,006	$13.90	A	87,387	D
Common Stock	Oct 24, 2018	M	29,080	$13.71	A	116,467	D
Common Stock	Oct 24, 2018	M	11,718	$13.71	A	128,185	D
Common Stock^F2	Oct 24, 2018	S	107,524	$127.74	D	20,661	D
Common Stock	Oct 24, 2018	G	12,012	$0.00	D	8,649	D
Common Stock	Oct 24, 2018	G	12,012	$0.00	A	12,012	I	By wife

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$23.85	Oct 24, 2018	M	9,596	D	—	Nov 5, 2022	Common Stock	9,596	116,009	D
Stock Option (right to buy)^F5	$13.90	Oct 24, 2018	M	39,006	D	—	Feb 27, 2025	Common Stock	39,006	17,860	D
Stock Option (right to buy)^F6	$13.71	Oct 24, 2018	M	29,080	D	—	Feb 28, 2026	Common Stock	29,080	7,899	D
Stock Option (right to buy)^F7	$13.71	Oct 24, 2018	M	11,718	D	—	Feb 28, 2026	Common Stock	11,718	12,873	D

Explanation of responses

F1These trades were made pursuant to a Rule 10b5-1 trading plan.
F2The shares were sold in multiple transactions at prices ranging from $120.87 to $134.39, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with the range set forth herein.
F3This transaction involved a gift of securities by the reporting person to his wife.
F4The option to purchase shares is fully vested.
F5The option vests based on time criteria (25% of the total option on 2/27/2016 and 1/48th of the total option in equal monthly installments thereafter).
F6Half of the total options granted began vesting when the FDA provided marketing approval for eteplirsen on 9/19/2016 and the other half of the total options granted began vesting when Sarepta Therapeutics, Inc. filed a Marketing Authorization Application with the European Medicines Agency on 11/30/2016. Vesting of the options allocated to the achievement of each goal is as follows: (i) 50% of the options allocated to the achieved goal vested immediately upon achievement of the performance condition (25% of the total performance-based options granted) and (ii) the remaining 50% of the options allocated to the achieved goal (25% of the total performance-based options granted) vest over four years. 25% of the remaining options vested on the first year anniversary of the grant date, or 2/28/2017 and 1/48th of the remaining options vests monthly thereafter.
F7The option vests based on time criteria (25% of the total option on 2/29/2017 and 1/48th of the total option in equal monthly installments thereafter).